The membrane-associated ubiquitin ligase MARCHF8 promotes cancer immune evasion by degrading MHC class I proteins

Mohamed I Khalil,Jie Wang,Canchai Yang,Lexi Vu,Congcong Yin,Smriti Chadha,Harrison Nabors,Daniel Vocelle,Danielle G May,Rachel J Chrisopolus,Li Zhou,Kyle G Roux,Matthew P Bernard,Qing-Sheng Mi,Dohun Pyeon

DOI: https://doi.org/10.1101/2024.11.29.626106

2024-12-06

Abstract:The loss of major histocompatibility complex class I (MHC-I) molecules has been proposed as a mechanism by which cancer cells evade tumor-specific T cells in immune checkpoint inhibitor (ICI)-refractory patients. Nevertheless, the mechanism by which cancer cells downregulate MHC-I is poorly understood. We report here that membrane-associated RING-CH-type finger 8 (MARCHF8), upregulated by human papillomavirus (HPV), ubiquitinates and degrades MHC-I proteins in HPV-positive head and neck cancer (HPV+ HNC). MARCHF8 knockdown restores MHC-I levels on HPV+ HNC cells. We further reveal that Marchf8 knockout significantly suppresses tumor growth and increases the infiltration of natural killer (NK) and T cells in the tumor microenvironment (TME). Furthermore, Marchf8 knockout markedly increases crosstalk between the cytotoxic NK cells and CD8+ T cells with macrophages and enhances the tumor cell-killing activity of CD8+ T cells. CD8+ T cell depletion in mice abrogates Marchf8 knockout-driven tumor suppression and T cell infiltration. Interestingly, Marchf8 knockout, in combination with anti-PD-1 treatment, synergistically suppresses tumor growth in mice bearing ICI-refractory tumors. Taken together, our finding suggests that MARCHF8 could be a promising target for novel immunotherapy for HPV+ HNC patients.

Cancer Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **How do human papillomavirus (HPV)-positive head and neck cancer (HPV + HNC) cells evade the recognition and attack of the immune system by down - regulating MHC - I molecules, thus leading to resistance to immune checkpoint inhibitor (ICI) treatment?**

Specifically, the paper explored the following issues:

1. **Expression of MHC - I molecules in HPV + HNC cells**:
- It was found that the expression of MHC - I molecules in HPV - positive head and neck cancer cells was significantly reduced, which may lead these cells to evade the recognition and killing by T cells.
- The authors experimentally verified that HPV viral proteins E6 and E7 can down - regulate the expression of MHC - I molecules.

2. **Role of MARCHF8 in MHC - I down - regulation**:
- MARCHF8 is a membrane - associated RING - CH - type ubiquitin ligase. It was found that it is highly expressed in HPV - positive head and neck cancer cells and can degrade MHC - I molecules through ubiquitination.
- By knocking down or knocking out MARCHF8, the expression of MHC - I molecules can be restored and the MHC - I level on the tumor cell surface can be increased.

3. **Effects of MARCHF8 knockout on tumor growth and the immune microenvironment**:
- MARCHF8 knockout not only restores the expression of MHC - I but also significantly inhibits tumor growth and increases the infiltration of NK cells and CD8+ T cells in the tumor microenvironment.
- These changes reshape the tumor microenvironment from an immunosuppressive state to an immunostimulatory state.

4. **Synergistic effect of MARCHF8 knockout and anti - PD - 1 treatment**:
- It was found that although MARCHF8 knockout can activate CD8+ T cells and inhibit tumor growth, it can also lead to the exhaustion of CD8+ T cells.
- Combining with anti - PD - 1 treatment can overcome this exhaustion, further enhance the anti - tumor effect, and show a synergistic effect in inhibiting tumor growth.

In summary, this paper reveals the mechanism by which MARCHF8 promotes immune evasion through ubiquitination - mediated degradation of MHC - I molecules in HPV - positive head and neck cancer cells, and proposes MARCHF8 as a potential immunotherapy target. Especially when used in combination with ICI, it may provide a new strategy for treating ICI - resistant HPV - positive head and neck cancer.